Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review
Jennifer L Caswell-Jin, Sylvia K Plevritis, Lu Tian, Christopher J Cadham, Cong Xu, Natasha K Stout, George W Sledge, Jeanne S Mandelblatt, Allison W Kurian, Jennifer L Caswell-Jin, Sylvia K Plevritis, Lu Tian, Christopher J Cadham, Cong Xu, Natasha K Stout, George W Sledge, Jeanne S Mandelblatt, Allison W Kurian
Abstract
Background: Metastatic breast cancer (MBC) treatment has changed substantially over time, but we do not know whether survival post-metastasis has improved at the population level.
Methods: We searched for studies of MBC patients that reported survival after metastasis in at least two time periods between 1970 and the present. We used meta-regression models to test for survival improvement over time in four disease groups: recurrent, recurrent estrogen (ER)-positive, recurrent ER-negative, and de novo stage IV. We performed sensitivity analyses based on bias in some studies that could lead earlier cohorts to include more aggressive cancers.
Results: There were 15 studies of recurrent MBC (N = 18 678 patients; 3073 ER-positive and 1239 ER-negative); meta-regression showed no survival improvement among patients recurring between 1980 and 1990, but median survival increased from 21 (95% confidence interval [CI] = 18 to 25) months to 38 (95% CI = 31 to 47) months from 1990 to 2010. For ER-positive MBC patients, median survival increased during 1990-2010 from 32 (95% CI = 23 to 43) to 57 (95% CI = 37 to 87) months, and for ER-negative MBC patients from 14 (95% CI = 11 to 19) to 33 (95% CI = 21 to 51) months. Among eight studies (N = 35 831) of de novo stage IV MBC, median survival increased during 1990-2010 from 20 (95% CI = 16 to 24) to 31 (95% CI = 24 to 39) months. Results did not change in sensitivity analyses.
Conclusion: By bridging studies over time, we demonstrated improvements in survival for recurrent and de novo stage IV MBC overall and across ER-defined subtypes since 1990. These results can inform patient-doctor discussions about MBC prognosis and therapy.
Figures
References
- Torre LA, Islami F, Siegel RL, et al. Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev. 2017;264:444–457.
- Siegel RL, Miller KD, Jemal A.. Cancer statistics, 2017. CA Cancer J Clin. 2017;671:7–30.
- Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;35317:1784–1792.
- Plevritis SK, Munoz D, Kurian AW, et al. Association of screening and treatment with breast cancer mortality by molecular subtype in US women, 2000–2012. JAMA. 2018;3192:154–164.
- Mariotto AB, Etzioni R, Hurlbert M, et al. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017;266:809–815.
- Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN guidelines insights: breast cancer, version 1.2017. J Natl Compr Canc Netw. 2017;154:433–451.
- Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;3525:2875–2884.
- Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;3532:3638–3646.
- Hortobagyi GN. Ribociclib for HR-positive, advanced breast cancer. N Engl J Med. 2017;3763:289.
- Canellos GP, Pocock SJ, Taylor SG 3rd, et al. Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard. Cancer. 1976;385:1882–1886.
- Jones S, Winer E, Vogel C, et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol. 1995;1310:2567–2574.
- Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol. 1999;175:1413–1424.
- Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005;2324:5542–5551.
- O’Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;2012:2812–2823.
- Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;3779769:914–923.
- Dieras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;186:732–742.
- Swain SM, Kim SB, Cortes J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;146:461–471.
- Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;34411:783–792.
- Stockler MR, Harvey VJ, Francis PA, et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol. 2011;2934:4498–4504.
- Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;2624:3950–3957.
- Ellis MJ, Llombart-Cussac A, Feltl D, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. J Clin Oncol. 2015;3332:3781–3787.
- Mauri D, Polyzos NP, Salanti G, et al. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst. 2008;10024:1780–1791.
- Li J, Ren J, Sun W.. Systematic review of ixabepilone for treating metastatic breast cancer. Breast Cancer. 2017;242:171–179.
- Gibson L, Lawrence D, Dawson C, et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2009;4:CD003370.
- Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer. 2004;1001:44–52.
- Rogoz B, Houze de l'Aulnoit A, Duhamel A, et al. Thirty-year trends of survival and time-varying effects of prognostic factors in patients with metastatic breast cancer-a single institution experience. Clin Breast Cancer. 2017; doi:10.1016/j.clbc.2017.08.012.
- Tevaarwerk AJ, Gray RJ, Schneider BP, et al. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer. 2013;1196:1140–1148.
- Nakano M, Fujisue M, Tashima R, et al. Survival time according to the year of recurrence and subtype in recurrent breast cancer. Breast. 2015;245:588–593.
- Largillier R, Ferrero JM, Doyen J, et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol. 2008;1912:2012–2019.
- Tsuji W, Teramukai S, Ueno M, et al. Prognostic factors for survival after first recurrence in breast cancer: a retrospective analysis of 252 recurrent cases at a single institution. Breast Cancer. 2014;211:86–95.
- Anan K, Mitsuyama S, Koga K, et al. Disparities in the survival improvement of recurrent breast cancer. Breast Cancer. 2010;171:48–55.
- Shigematsu H, Kawaguchi H, Nakamura Y, et al. Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000. BMC Cancer. 2011;11:118.
- Foukakis T, Fornander T, Lekberg T, et al. Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. Breast Cancer Res Treat. 2011;1302:553–560.
- Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer. 2005;1048:1742–1750.
- Sundquist M, Brudin L, Tejler G.. Improved survival in metastatic breast cancer 1985-2016. Breast. 2017;31:46–50.
- Chia SK, Speers CH, D'Yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;1105:973–979.
- Dafni U, Grimani I, Xyrafas A, et al. Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat. 2010;1193:621–631.
- Weide R, Feiten S, Friesenhahn V, et al. Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors. Springerplus. 2014;31:535..
- Giuliani J, Bonetti A.. Trends in survival for patients with metastatic breast cancer: is survival improving? Tumori. 2015;1014:347–352.
- Holleczek B, Arndt V, Stegmaier C, et al. Trends in breast cancer survival in Germany from 1976 to 2008—a period analysis by age and stage. Cancer Epidemiol. 2011;355:399–406.
- Ernst MF, van de Poll-Franse LV, Roukema JA, et al. Trends in the prognosis of patients with primary metastatic breast cancer diagnosed between 1975 and 2002. Breast. 2007;164:344–351.
- Pal SK, Dehaven M, Nelson RA, et al. Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer. BMC Cancer. 2012;12:435.
- Andre F, Slimane K, Bachelot T, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004;2216:3302–3308.
- Dawood S, Broglio K, Gonzalez-Angulo AM, et al. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol. 2008;2630:4891–4898.
- Ruiterkamp J, Ernst MF, de Munck L, et al. Improved survival of patients with primary distant metastatic breast cancer in the period of 1995-2008. A nationwide population-based study in the Netherlands. Breast Cancer Res Treat. 2011;1282:495–503.
- Knapp G, Hartung J.. Improved tests for a random effects meta-regression with a single covariate. Stat Med. 2003;2217:2693–2710.
- Jemal A, Ward EM, Johnson CJ, et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst. 2017;1099:djx030.
- Pavlik T, Majek O, Buchler T, et al. Trends in stage-specific population-based survival of cancer patients in the Czech Republic in the period 2000-2008. Cancer Epidemiol. 2014;381:28–34.
- Vogel CL, Azevedo S, Hilsenbeck S, et al. Survival after first recurrence of breast cancer. The Miami experience. Cancer. 1992;701:129–135.
- Zeichner SB, Ambros T, Zaravinos J, et al. Defining the survival benchmark for breast cancer patients with systemic relapse. Breast Cancer (Auckl.) 2015;9:9–17.
- Giuliani J, Bonetti A.. Trends in survival for patients with metastatic breast cancer: is survival improving? Tumori. 2015;1014:347–352.
- Di Meglio A, Freedman RA, Lin NU, et al. Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Res Treat. 2016;1573:587–596.
- Insa A, Lluch A, Prosper F, et al. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat. 1999;561:67–78.
- Chang J, Clark GM, Allred DC, et al. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer. 2003;973:545–553.
- Aebi S, Gelber S, Anderson SJ, et al. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol. 2014;152:156–163.
- Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006;2418:2743–2749.
- Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;35616:1670–1674.
- Dawood S, Broglio K, Ensor J, et al. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol. 2010;2111:2169–2174.
- Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;2925:3366–3373.
- Rocque G, Blayney DW, Jahanzeb M, et al. Choosing wisely in oncology: are we ready for value-based care? J Oncol Pract. 2017; doi:10.1200/JOP.2016.019281.
- Tao L, Chu L, Wang LI, et al. Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population. Cancer Causes Control. 2016;279:1127–1138.
- Whyte JL, Engel-Nitz NM, Teitelbaum A, et al. An evaluation of algorithms for identifying metastatic breast, lung, or colorectal cancer in administrative claims data. Med Care. 2015;537:e49–e57.
- Nordstrom BL, Whyte JL, Stolar M, et al. Identification of metastatic cancer in claims data. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 2:21–28.
- Hassett MJ, Ritzwoller DP, Taback N, et al. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care. 2014;5210:e65–e73.
- Earle CC, Nattinger AB, Potosky AL, et al. Identifying cancer relapse using SEER-Medicare data. Med Care. 2002;40(8 Suppl):IV-75–IV-81.
- Chubak J, Yu O, Pocobelli G, et al. Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer. J Natl Cancer Inst. 2012;10412:931–940.
- Chawla N, Yabroff KR, Mariotto A, et al. Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage. Ann Epidemiol. 2014;249:666–672.e1–2.
- Warren JL, Mariotto A, Melbert D, et al. Sensitivity of medicare claims to identify cancer recurrence in elderly colorectal and breast cancer patients. Med Care. 2013; doi:.
- Penberthy L, Petkov V, McClish D, et al. The value of billing data from oncology practice to supplement treatment information for cancer surveillance. J Registry Manag. 2014;412:57–64.
- Sledge GW Jr, Miller RS, Hauser R.. CancerLinQ and the future of cancer care. Am Soc Clin Oncol Educ Book 2013;33430:430–434.
- Colwell J. FDA Partners with ASCO's CancerLinQ. Cancer Discov 2017;78:OF2.
- Lau EC, Mowat FS, Kelsh MA, et al. Use of electronic medical records (EMR) for oncology outcomes research: assessing the comparability of EMR information to patient registry and health claims data. Clin Epidemiol. 2011;3:259–272.
- Warren JL, Yabroff KR.. Challenges and opportunities in measuring cancer recurrence in the United States. J Natl Cancer Inst. 2015;1078:djv134.
- Penberthy L. Research grade data from cancer registries—the SEER perspective American Society of Clinical Oncology annual meeting, 2017; Chicago, IL.
- Munoz D, Near AM, van Ravesteyn NT, et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst. 2014;10611:dju289.
Source: PubMed